BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhattacharyya A, Rai SN. Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design. Contemp Clin Trials Commun 2019;15:100378. [PMID: 31289760 DOI: 10.1016/j.conctc.2019.100378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med 2020;18:352. [PMID: 33208155 DOI: 10.1186/s12916-020-01808-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Demmy TL. Commentary: Expanding the legacy of unusual malignancy research. J Thorac Cardiovasc Surg 2020;159:715-6. [PMID: 31711618 DOI: 10.1016/j.jtcvs.2019.09.108] [Reference Citation Analysis]
3 Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer 2022;10:e003231. [PMID: 35022192 DOI: 10.1136/jitc-2021-003231] [Reference Citation Analysis]